NASS has recently posted the revised draft Coverage Recommendations of Recombinant Human Bone Morphogenetic Protein rhBMP-2 for a 30-day public comment period, open through February 20, 2026. 

Click here to read the coverage recommendation.

Your feedback is crucial in this process and we encourage all interested parties to share comments with us at coverage@spine.org.